ClinicalTrials.gg

Program

ruxoprubart

Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome · Dermatomyositis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, led by NovelMed Therapeutics.

Furthest: phase 2, since Nov 18, 20229 company-led studies, 8 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NovelMed Therapeutics98 open or runningphase 2since Nov 18, 2022Nov 18, 2022Aug 2027phase 2 · NCT05646524

Also a collaborator on its studies: labcorp-corporation-of-america-holdings-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2022First studies: 3 phase 2 studiesFirst studyNCT05647811, NCT05646563, NCT05646524
  2. Nov 18, 2022Phase 1 study in HealthyNCT05642546 · 40 enrolled · United States
  3. Jan 4, 2023Phase 2 study in Atypical Hemolytic Uremic SyndromeNCT05684159 · 12 planned
  4. Feb 1, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT05731050 · 6 planned
  5. Jan 18, 2024Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06226662 · 12 planned
  6. Jun 6, 2024Phase 2 study in Glomerulonephritis, IGANCT06454110 · 10 planned
  7. Mar 7, 2025Phase 2 study in DermatomyositisNCT06887738 · 8 planned

Ahead

  1. Aug 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT05646524
  2. Sep 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT05731050
  3. Oct 2027Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06226662
  4. Nov 2027Primary completion: phase 2 study in DermatomyositisNCT06887738

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06887738Dermatomyositis2Not yet recruitingNov 20278
NCT06454110Glomerulonephritis, IGA2Not yet recruitingDec 203010
NCT06226662Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis2Not yet recruitingOct 202712
NCT05731050Hemoglobinuria, Paroxysmal2Not yet recruitingSep 20276
NCT05684159Atypical Hemolytic Uremic Syndrome2Not yet recruitingApr 203012
NCT05646563Hemoglobinuria, Paroxysmal2Not yet recruitingJul 202912
NCT05646524Hemoglobinuria, Paroxysmal2Not yet recruitingAug 202712
NCT05647811C3 Glomerulopathy2Not yet recruitingAug 202918
NCT05642546Healthy · United States1CompletedJun 15, 202240

How it is read

Names in the registry

  • “NM8074”, 9 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.